Spermosens are active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization. The largest operations are in the Nordic market.

Quotes for Spermosens AB (publ)

Created with Highstock 6.0.7CloseTraded Volume17. feb24. feb3. mar10. mar17. mar24. mar31. mar7. apr21. apr28. apr5. maj12. maj0.0040.0060.0080.010.012080M160M240M320M

Right Now

+/-
0.0002
%
2,56%
Latest
0.008
High
0.008
Low
0.0072
Volume
11 214 708
Turnover (SEK)
84 520
Market Value (MSEK)
10,8
Time (Latest trade)

Board

CEO

  • Tore Duvold

Chairperson of the Board

  • Ulrik Spork

Board

  • Christina Östberg Lloyd
  • Ingela Liljeqvist Soltic
  • Kushagr Punyani
  • Sören Melsing Frederiksen

Largest Owners

Name Capital % Votes % Date
Mount Nebo Capital 24,95 24,95 2025-03-04
Flexmedical Solutions Limited 6,32 6,32 2025-02-17
UNITY Innovation Alliance AG 5,17 5,17 2025-03-04
Henrik Ruö Jensen 3,65 3,65 2025-03-27
Michael Kantor 3,41 3,41 2025-03-27
Avanza Pension 2,85 2,85 2025-03-27
Nordnet Pensionsförsäkring 2,49 2,49 2025-03-27
Per Robert Anderson 1,85 1,85 2025-03-27
Olof Hedin 1,12 1,12 2025-03-27
Johann Bech Vedsmand 0,98 0,98 2025-03-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

NameTransaction DateTypeInstrumentAmountPriceValueCurrency
Ulrik Nilsson2024-12-23Sell TransactionSpermosens- 4 400 0060,01−50 160,1SEK
Ulrik Nilsson2024-04-17en-USSPERM BTU 250 0000,7175 000,0SEK
Eva Nilsagård2024-04-17en-USSPERM BTU 102 0000,771 400,0SEK
Ulrik Nilsson2023-05-29Buy TransactionSpermosens 68 1000,6946 989,0SEK
Kushagr Punyani2023-01-30en-USBTU 59 5240,8450 000,2SEK
Søren Melsing Frederiksen2023-01-25en-US BTU 175 0000,84147 000,0SEK
John Lempert2023-01-23en-USSpermosens UR 23 8080,8419 998,7SEK
Ulrik Nilsson2023-01-23en-USSpermosens BTU 128 4000,84107 856,0SEK
Eva Nilsagård2023-01-23en-USSpermosens BTU 72 0000,8460 480,0SEK
John Lempert2023-01-23en-USSpermosens UR 9 9200,848 332,8SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 47 5000,14−6 650,0SEK
Kushagr Punyani2023-01-16Sell TransactionSpermosens UR- 250 0000,11−27 500,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 110 0000,17−18 700,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 90 0000,17−15 300,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 78 3690,17−13 322,7SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 70 0000,17−11 900,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 62 0000,24−14 880,0SEK
Kushagr Punyani2023-01-16Sell TransactionSpermosens UR- 60 0000,15−9 000,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 50 0000,2−10 000,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 50 0000,14−7 000,0SEK
Kushagr Punyani2023-01-16Sell TransactionSpermosens UR- 50 0000,14−7 000,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 45 0000,24−10 800,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 40 0000,17−6 800,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 30 0000,24−7 200,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 30 0000,13−3 900,0SEK
Kushagr Punyani2023-01-16Sell TransactionSpermosens UR- 26 5000,13−3 445,0SEK
Kushagr Punyani2023-01-18Sell TransactionSpermosens UR- 6 3220,22−1 390,8SEK
Kushagr Punyani2023-01-16Sell TransactionSpermosens UR- 22 6000,12−2 712,0SEK
Kushagr Punyani2023-01-16Sell TransactionSpermosens UR- 19 9490,15−2 992,3SEK
Ulrik Nilsson2022-06-22en-USPersonaloptionsprogram 2022/2025 190 00000,0SEK
John Lempert2022-05-25en-USSpermosens- 25 0000−0,0SEK
John Lempert2022-05-25en-USSpermosens 35 52412,29436 590,0SEK
John Lempert2022-05-25en-USSpermosens TO1- 35 5240−0,0SEK
Ulrik Nilsson2022-05-25en-USSpermosens 10 00012,29122 900,0SEK
Ulrik Nilsson2022-05-25en-USSpermosens 25 00000,0SEK
Ulrik Nilsson2022-05-25en-USSpermosens TO1- 10 0000−0,0SEK
Ulrik Nilsson2022-05-04Buy TransactionSpermosens TO1 10 0000,44 000,0SEK
Mosike Thabitha Carlsson2021-05-17Buy TransactionSpermosens 6509,155 947,5SEK
Mosike Thabitha Carlsson2021-05-21Buy TransactionSpermosens 5 0008,9644 800,0SEK
Eva Nilsagård2021-05-10Buy TransactionSpermosens 30 0009,9297 000,0SEK
Cajsa Wramdemark2021-05-07en-USSpermosens 3 9955,6322 491,8SEK
Cajsa Wramdemark2021-04-30en-USSPERMOSENS/SH 8 8815,6350 000,0SEK
Søren Melsing Frederiksen2021-04-21en-USSpermosens 169 1325,63952 213,2SEK
John Moll2021-04-16en-USSpermosens 37 7665,63212 622,6SEK
John Moll2021-04-19en-USSpermosens 37 3005,63209 999,0SEK
John Lempert2021-04-15en-USSpermosens 25 5245,63143 700,1SEK
Oscar Nilsagård2021-04-16en-USSpermosens 3 0005,6316 890,0SEK
*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

2025-03-312024-12-312024-12-312024-09-302024-06-302024-03-312023-12-31
Number of months that the report spans Q1 3 Months2024Q4 3 MonthsQ3 3 MonthsQ2 3 MonthsQ1 3 Months2023
Total revenue MSEK0.000.000.000.000.000.000.00
Earnings before interest and tax MSEK-2.06-9.16-2.37-2.13-2.06-2.60-10.87
Profit before tax MSEK-2.07-10.20-2.46-2.16-2.37-3.22-12.20
Net profit MSEK-2.07-10.20-2.46-2.16-2.37-3.22-12.20
Earnings per share SEK-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Dividend per share SEK0.000.00
Equity MSEK38.1027.3527.3521.9724.138.8212.69
Fixed assets MSEK0.420.460.460.520.560.610.65
Intangible assets MSEK24.9124.3424.3423.7422.8421.4719.74
Current assets MSEK3.811.761.760.743.901.745.72
Total asset MSEK39.9431.0431.0425.0027.3023.8226.11
Long term liabilities MSEK0.000.000.000.030.050.080.23
Current liabilities MSEK1.843.703.702.993.1215.0013.18
Number of shares SEK1356.18283.61283.61283.61283.6141.1941.19
*Compiled data from Millistream

Upcoming reports

  • 2025-08-20 Delårsrapport 2025-Q2

  • 2025-11-12 Delårsrapport 2025-Q3